Compare Eli Lilly And Co (LLY) vs Blue Owl Capital Inc. Class A Common Stock (OWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Blue Owl Capital Inc. Class A Common Stock — how do they compare? Eli Lilly And Co trades at $1,227 (market cap $1.08T), while Blue Owl Capital Inc. Class A Common Stock trades at $8.8 (market cap $6.01B). The key difference: Eli Lilly And Co is far larger — about 179.7× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays the higher dividend (10.35%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and Blue Owl Capital Inc. Class A Common Stock for 0 Days on average.
| LLY | OWL | |
|---|---|---|
Market Cap | $1.08T | $6.01B |
Volume | 2,520,401 | 24,327,195 |
Sector | Health | Financials |
52-Week High | $1.28K | $17.17 |
52-Week Low | $799.57 | $8.23 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $1.12T | $10.19B |
Dividend Yield | 0.57% | 10.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,166.51, down 1.36% on the day, amid strong fundamentals with revenue surging to $65.18B in 2025 and net income reaching $20.64B. The stock exhibits a bullish technical trend, supported by moving averages, with key resistance near $1,190. Recent news highlights promising pipeline developments in weight-loss drugs, reinforcing growth prospects.
Outlook remains positive given robust earnings beats, high analyst buy ratings (73%), and a consensus price target of $1,350. Risks include competitive pressures and execution challenges in scaling production. The stock's premium valuation (P/E 39.16) warrants monitoring, but strong cash flow and innovation pipeline support long-term upside.
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →
